抗结核药联合胸腺法新治疗初治涂阳肺结核48例的临床效果

Clinical effect of anti-TB drug combined with thymalfasin in 48 cases of initial smear-positive pulmonary tuberculosis

目的观察抗结核药联合胸腺法新治疗初治涂阳肺结核的临床效果。方法选取2015年3月至2016年2月我院收治的96例初治涂阳肺结核患者为研究对象,将其按照随机数表法分为两组,分别为对照组(48例,抗结核药治疗)和治疗组(48例,抗结核药+胸腺法新治疗)。比较两组患者的痰菌阴转、病灶吸收情况、临床效果及不良反应发生情况。结果治疗后1个月,两组患者痰菌阴转率比较,差异不明显(P>0.05);治疗后3、6、9个月,治疗组患者痰菌阴转率均明显高于对照组(P<0.05);治疗后6、9个月,治疗组病灶吸收总有效率明显高于对照组(P<0.05);治疗后6、9个月,治疗组的临床总有效率分别为95.83%、93.75%,均明显高于对照组的79.17%、81.25%(P<0.05);两组患者的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论抗结核药联合胸腺法新治疗初治涂阳肺结核可以改善患者痰菌阴转情况及病灶吸收情况,提高治疗总有效率,并且安全性高,不良反应发生率低,值得临床推广与应用。

Objective To observe the clinical effect of anti-TB drug combined with thymalfasin in 48 cases of initial smear-positive pulmonary tuberculosis. Methods Ninety-six patients with initial smear-positive pulmonary tuberculosis admitted in our hospital from March 2015 to February 2016 were selected and divided into control group（48 cases, treated with anti-tuberculous drug） and treatment group（48 cases, treated with anti-tuberculosis drug＋thymalfasin） according to the random number method. The phlegm negative transfer, lesion absorption, clinical efficiency and incidence of adverse reactions were compared between the two groups. Results One month after treatment, there was no significant difference in sputum negative conversion rate between the two groups（P〈0.05）. At 3, 6 and 9 months after treatment, the sputum negative conversion rates in the treatment group were significantly higher than those in the control group（P〈0.05）. At 6 and9 months after treatment, the total effective rates of lesion absorption in the treatment group were higher than those in the control group（P〈0.05）. At 6 and 9 months after treatment, the total effective rate of treatment in the treatment group were95.83%, 93.75% respectively, which were higher than 79.17%, 81.25% in the control group（P〈0.05）. There was no significant difference in the total incidence of adverse reactions between the two groups（P〈0.05）. Conclusion Anti-TB drug combined with thymalfasin in the treatment of initial smear-positive pulmonary tuberculosis can improve the phlegm negative transfer and lesion absorption, improve the total efficiency of treatment, with high safety and low incidence of adverse reactions, which is worthy of clinical promotion and application.